文献速递中毒与环境急症重症综合管理与镇静镇痛

毒扁豆碱逆转第二代抗精神病药暴露所致谵妄:区域中毒中心的回顾性队列研究

Physostigmine reversal of delirium from second generation antipsychotic exposure: a retrospective cohort study from a regional poison center.
PubMed 文献 · Clin Toxicol (Phila) · 2024-07-10
一句话结论单区域中毒中心回顾性队列显示,毒扁豆碱逆转第二代抗精神病药所致抗胆碱能谵妄的阳性反应率为82.8%,不良事件发生率2.9%(含1例死亡)。

该研究为单区域中毒中心回顾性队列,纳入2000年1月1日至2021年4月15日因第二代抗精神病药暴露后接受毒扁豆碱治疗的患者138例,其中128例有反应记录。最常见暴露药物为喹硫平(97例,70.3%)。毒扁豆碱阳性反应率为106/128(82.8%)[95%CI 68.9-83.6%],中位给药次数1次(IQR 1-3,范围1-9),中位总剂量2 mg(IQR 2-6 mg,范围0.15-30 mg)。抗胆碱能共摄入组与其他共摄入或无共摄入组的阳性反应率无显著差异(25/34 vs 81/94,P=0.09)。不良事件4例(2.9%),包括出汗、癫痫、心动过缓各1例(0.7%),1例(0.7%)在用药60分钟后发生心脏骤停并死亡。作者认为毒扁豆碱似乎安全有效,但需进一步研究验证。

要点

  • 第二代抗精神病药暴露所致抗胆碱能谵妄中,毒扁豆碱阳性反应率为106/128(82.8%)[95%CI 68.9-83.6%]。
  • 最常见暴露药物为喹硫平(97例,70.3%);中位给药次数1次(IQR 1-3,范围1-9),中位总剂量2 mg(IQR 2-6 mg,范围0.15-30 mg)。
  • 抗胆碱能共摄入组与其他共摄入或无共摄入组的阳性反应率无显著差异(25/34 vs 81/94,P=0.09)。
  • 不良事件4例(2.9%):出汗1例(0.7%)、癫痫1例(0.7%)、心动过缓1例(0.7%),另1例(0.7%)在用药60分钟后心脏骤停并死亡。
  • 作者认为毒扁豆碱似乎安全有效,但需进一步研究验证其安全性和有效性。

适用人群与场景

  • 2000年1月1日至2021年4月15日期间报告至单区域中毒中心、因第二代抗精神病药暴露后接受毒扁豆碱治疗的全部患者。
  • 共审查147份病历,纳入138例独立患者,其中128例有对毒扁豆碱的反应记录。

处置流程与药物剂量

  • 毒扁豆碱用于逆转第二代抗精神病药暴露所致抗胆碱能谵妄;中位给药次数1次(IQR 1-3,范围1-9),中位总剂量2 mg(IQR 2-6 mg,范围0.15-30 mg),具体单次剂量、给药途径和频次原文未写明。

红旗征与不能漏的情况

  • 不良事件包括出汗1例(0.7%)、癫痫1例(0.7%)、心动过缓1例(0.7%)。
  • 1例(0.7%)患者在因过去一个月内克洛氮平剂量递增后出现抗胆碱能谵妄、接受毒扁豆碱治疗60分钟后发生心脏骤停并死亡。

研究设计与关键结果

  • 研究类型:回顾性队列研究,单区域中毒中心,纳入138例独立患者(审查147份病历),其中128例有对毒扁豆碱的反应记录。
  • 最常见第二代抗精神病药暴露为喹硫平(97例,70.3%)。
  • 主要结局:毒扁豆碱阳性反应率106/128(82.8%)[95%CI 68.9-83.6%]。
  • 中位毒扁豆碱给药次数1次(IQR 1-3,范围1-9);中位总剂量2 mg(IQR 2-6 mg,范围0.15-30 mg)。
  • 抗胆碱能共摄入组与其他共摄入或无共摄入组的阳性反应率无显著差异(25/34 vs 81/94,P=0.09)。
  • 不良事件4例(2.9%):出汗1例(0.7%)、癫痫1例(0.7%)、心动过缓1例(0.7%);1例(0.7%)在用药60分钟后发生心脏骤停并死亡。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,毒扁豆碱似乎是治疗第二代抗精神病药暴露所致抗胆碱能谵妄的安全有效方法;需进一步研究验证其在该适应证中的安全性和有效性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Physostigmine is an effective antidote for antimuscarinic delirium. There is little evidence for its use to reverse delirium following second generation antipsychotic exposure. The purpose of this study is to describe the safety and effectiveness of physostigmine in reversing delirium from second generation antipsychotic exposure.

METHODS: This is a retrospective cohort study of all patients reported to a single regional poison center treated with physostigmine following a second generation antipsychotic exposure from January 1, 2000 to April 15, 2021. The poison center electronic medical record was queried to identify cases and for data abstraction. The primary outcome was the positive response rate to physostigmine, as determined by two trained abstractors. Secondary outcomes included physostigmine dosing, and adverse events.

RESULTS: Of 147 charts reviewed, 138 individual patients were included, and the response to physostigmine was reported in 128 patients. The most common second-generation antipsychotic exposure was quetiapine (97; 70.3 percent). A positive response to physostigmine was noted in 106/128 (82.8 percent) patients [95 percent confidence interval 68.9-83.6 percent]. Median number of physostigmine doses was 1 (interquartile range 1-3; range 1-9). The median total physostigmine dose received was 2 mg (interquartile range 2-6 mg; range 0.15-30 mg). The positive physostigmine response rate for patients with an antimuscarinic co-ingestion was not significantly different compared to patients with a different co-ingestion or no co-ingestion (25/34 versus 81/94; P = 0.09). Adverse events were reported in four (2.9 percent) patients, including one death.

DISCUSSION: A positive response to physostigmine to treat antimuscarinic delirium from second generation antipsychotic exposure was reported in 82.8 percent of patients, which is similar to previous physostigmine studies. Adverse events were infrequent, and included diaphoresis (one 0.7 percent), seizure (one; 0.7 percent), and bradycardia (one; 0.7 percent). One (0.7%) patient suffered a cardiac arrest 60 minutes after receiving physostigmine to treat antimuscarinic delirium following having received increasing clozapine doses over the previous month.

CONCLUSIONS: In this study, physostigmine appears to be a safe and effective treatment for antimuscarinic delirium from second generation antipsychotic exposure. Further studies are needed to validate the safety and effectiveness of physostigmine for this indication.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Arens AM, Sheikh Said H, Driver BE, et al. Physostigmine reversal of delirium from second generation antipsychotic exposure: a retrospective cohort study from a regional poison center. Clin Toxicol (Phila). 2024. PMID: 38984853. doi:10.1080/15563650.2024.2373850

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。